In secondary MR, the MR is the consequence of other diseases that have injured the LV. Not surprisingly, curing MR does not cure the myocardial infarctions or dilated cardiomyopathy that caused the MR in the first place. Thus, restoration of mitral competence in this disease does not convincingly improve longevity, although it does improve quality of life (8) (9) (10) . In a recent trial randomizing patients with secondary MR to receive mitral repair versus mitral valve replacement, the 1-year mortality was 15%, and mitral repair, the gold standard of therapy for primary MR, was no better than mitral valve replacement (10), reflecting the differences in therapy for the 2 diseases.
With that background, 2 papers in this issue of the Journal report the results of percutaneous repair using the MitraClip, a device that reduces MR by apposing the two mitral leaflets at their midsections (11, 12) .
THERAPY FOR PRIMARY MR
As noted above, mitral valve repair is the preferred therapy for treating primary MR. Repair maintains LV function and can restore lifespan to normal when practiced in expert hands and when timed before severe LV dysfunction has been allowed to occur (5, (13) (14) (15) . That said, we must look at our collective selves as a cardiovascular community in the mirror.
A substantial number of cardiologists do not know the importance of repair, the triggers for referral to a surgeon, or the repair rate in their own hospitals (16) . Additionally, unfortunately, although some centers accomplish very high repair rates (17) , a recent query of the Society of Thoracic Surgeons (STS) database found that the average U.S. surgeon repaired less than 50% of mitral valves on which they operated, and on average, U.S. surgeons performed fewer than one-half a dozen mitral operations of any kind in a year (18) The authors' determination of prohibitive risk seems fair, but pulmonary hypertension and risk of aspiration seem somewhat arbitrary as many patients with either condition can undergo an operation safely, albeit at higher than average risk.
Furthermore, the fact that a few patients underwent surgery vitiates the term prohibitive because Webster defines "prohibitive" as "serving as to preclude the use of something." Obviously, surgery was not precluded. It has become obvious that no risk score fully can account for all the variables that enter into the risk of surgery, although the STS score seems to give a good, although often overestimated, appraisal of risk (19) . Regardless, no score should supersede the judgment of a heart team that takes into account both the tangible and intangible factors that contribute to surgical risk, and in the patients reported here, surgery was considered infeasible.
That said, we in the medical community must do a better job of standardizing our terminology. 
THERAPY FOR SECONDARY MR
The ultimate therapy for secondary MR should be to restore the contractile elements or the force generation of those elements, thereby returning ventricular function to normal, allowing the LV to remodel in such a way as to restore mitral competence. Although such therapies hold promise for the future, they currently are unavailable for general use. Accordingly, we treat patients with secondary MR by using guideline-driven therapies for the heart failure that the patients almost inevitably have. This distinction for secondary MR patients derives from the fact that MR is not the primary cause of heart failure but rather a complication of it. Not surprisingly, surgery has produced disappointing results with regard to increasing lifespan, because it does not cure the loss of contractility that caused the MR in the first place (8-10). However, surgery does improve symptoms in some but not all cases. Thus, the bar for treating this disease is much lower than it is for primary MR.
Accordingly, it is harder to draw conclusions from the paper by Glower et al. (12) , where patients with the 2 different diseases were admixed (70% had functional MR) (13) . High risk was defined by both the STS score and/or the presence of pre-specified risk factors. Thirty-day mortality (4.8%) and 1-year mortality (23%) were remarkably similar to the pure primary MR group reported by Lim et al. (11) . Eighty-six percent had post-procedure MR severity of moderate or less. As in the study by Lim et al. (11) , there was significant improvement in quality of life following the "clip" procedure. Although in this study, it was impossible to tease out differences in primary and secondary MR, which surely existed, future reports will surely be aimed at this discrimination.
WHAT HAVE WE LEARNED FROM THESE STUDIES?
The 2 studies noted above demonstrate that reduction in MR improves the quality of life in patients at increased risk for surgical repair. In the future, to fully understand the role of percutaneous MR repair, we must study it separately in the 2 very different diseases for which it is being applied, so we can define its role in primary versus secondary MR. Furthermore, we must more precisely define our terms used to stratify risk in randomized trials to fully apply the trial results to our patients.
